Improved Outcomes Among Newly Diagnosed Patients with FLT3-ITD Mutated AML Treated with Contemporary Therapy: Revisiting the ELN Adverse Risk Classification.
Sign Up to like & getrecommendations! Published in 2022 at "American journal of hematology"
DOI: 10.1002/ajh.26451
Abstract: Mutations in in fms-like tyrosine kinase 3 (FLT3) gene are common genomic alterations in acute myeloid leukemia (AML). FLT3 internal tandem duplication mutations (FLT3-ITD) have consistently been shown to be adversely prognostic, particularly those with… read more here.
Keywords: eln adverse; patients flt3; adverse risk; flt3 mutations ... See more keywords
EP463 Endometrial cancer recurrence in low risk patients - analysis of potential adverse risk factors in the experience of a single center
Sign Up to like & getrecommendations! Published in 2019 at "International Journal of Gynecological Cancer"
DOI: 10.1136/ijgc-2019-esgo.522
Abstract: Introduction/Background Patients with endometrial cancer of low risk (stage IA G1) are recommended for observation or adjuvant therapy (brachytherapy), as recommendations allow, on the basis of the presence of potential adverse risk factors such as:… read more here.
Keywords: risk; potential adverse; risk factors; adverse risk ... See more keywords
Routine Use of Gemtuzumab Ozogamicin in 7+3-Based Inductions for All "Non-Adverse" Risk AML
Sign Up to like & getrecommendations! Published in 2020 at "Blood"
DOI: 10.1182/blood-2020-142691
Abstract: Introduction: The addition of gemtuzumab ozogamicin (GO) to 7+3 chemotherapy for newly diagnosed acute myeloid leukemia (AML) has been shown to significantly improve event-free survival (EFS) for cytogenetically favorable-risk AML, with marginal benefit for intermediate-risk… read more here.
Keywords: risk; adverse risk; membership entity; risk pts ... See more keywords